Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT07801820

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Shanghai Minwei Biotechnology Co., Ltd (from the registry)
Registry
  • NCT NCT07801820
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07801820. Randomized; double masking; primary purpose treatment. Start 2026-06-23 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
MWN109 1
Intervention (Drug)
MWN109 2
Intervention (Drug)
MWN109 3
Intervention (Drug)
MWN109 4
Intervention (Drug)
Placebo
Intervention (Drug)
Semaglutide Tablets
Lead sponsor
Shanghai Minwei Biotechnology Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07801820
Content hash
1bb7f9d13a4a02d2f74ebe7b4647a247fa8e86bf2d73b3881809962ef01c4c3e